Hepatitis B Virus Genotypes in the Kingdom of Bahrain: Prevalence, Gender Distribution and Impact on Hepatic

Essam M Janahi1, Zahra Ilyas2, Sara Al-Othman3

  • 1Department of Biology, College of Science, University of Bahrain, Shakir P.O. Box 32038, Bahrain. essam22@gmail.com.

Medicina (Kaunas, Lithuania)
|September 25, 2019
PubMed

Insights

Hepatitis B virus (HBV) genotype D is most common in Bahrain, affecting males and non-Bahrainis more. Genotype D correlates with elevated liver enzymes like ALT and GGT.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) infection is a global health concern, affecting approximately 400 million people worldwide.
  • Limited data exists on HBV genotype prevalence and risk factors in the Kingdom of Bahrain.
  • Understanding these factors is crucial for effective disease control and management.

Purpose of the Study:

  • To determine the prevalence of different Hepatitis B virus genotypes in Bahrain.
  • To investigate the correlation between HBV genotypes and demographic factors.
  • To assess the impact of HBV genotypes on hepatic biomarkers.

Main Methods:

  • Blood samples from 82 HBV-positive patients were analyzed for HBV DNA extraction and genotyping.
  • Genotypes were classified using PCR amplification.
  • Statistical analyses (descriptive statistics, ANOVA, t-test) were used to determine associations with demographic factors and liver function tests.

Main Results:

  • Hepatitis B virus genotype D was predominant (61%), followed by genotype A (10%).
  • No significant associations were found between genotypes and most demographic factors or liver function tests.
  • HBV prevalence was higher in males and non-Bahraini individuals. Patients with genotype D showed elevated ALT and GGT levels.

Conclusions:

  • Hepatitis B virus genotype D is the most prevalent in Bahrain, followed by genotype A.
  • Further research into transmission sources and biomarker impacts is needed for enhanced HBV control in Bahrain.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
186
Probability Laws01:49

Probability Laws

Overview
43.9K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217
Pedigree Analysis01:35

Pedigree Analysis

Overview
88.9K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
217